Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.

Although the reduction in liver fat content did not reach statistical significance, there was a noticeable improvement in glycemic parameters (fasting plasma glucose and HbA1c) in the PXL770 group. 88 With ongoing advancements in pharmacology, it is conceivable that more effective medications will become available to improve the treatment of MASH and T2DM.

also in 111,027 other papers